A Phase 2 Study of Intrapatient Siltuximab Dose Escalation in Patients With Idiopathic Multicentric Castleman Disease That Has Progressed After Prior Siltuximab Treatment
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Siltuximab (Primary)
- Indications Giant lymph node hyperplasia
- Focus Therapeutic Use
- Acronyms SISREMCAD
- Sponsors EUSA Pharma
- 15 Apr 2021 Status changed from not yet recruiting to discontinued due to Internal Company Decision.
- 14 Apr 2021 New trial record